Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Codeine + promethazine** is a combination drug commonly used in oral syrup or solution form for the temporary relief of cough and upper respiratory symptoms associated with allergies or the common cold[1][5][6]. **Promethazine** is a first-generation antihistamine of the phenothiazine class that works by blocking H1 histamine receptors, reducing symptoms like sneezing, runny nose, and congestion. It also has antidopaminergic, anticholinergic, and sedative properties. **Codeine** is a natural opioid that acts as an agonist at mu-opioid receptors in the central nervous system, suppressing the cough reflex and providing mild analgesic effects[1][3][12]. The combination is indicated for adults and not recommended for children under 18 due to risk of respiratory depression and other serious adverse events[6]. This product is available only by prescription.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine + promethazine.